{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:53:54Z","timestamp":1789016034380,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["2008-4333"],"award-info":[{"award-number":["2008-4333"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["2008-4333"],"award-info":[{"award-number":["2008-4333"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"name":"This study was financially supported by BMS\/Celgene and Roche. BMS\/Celgene and Roche had no role in the design, analysis and interpretation of the results nor in writing of the article"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A randomized phase-II study was performed in low\/int-1 risk MDS (IPSS) to study efficacy and safety of lenalidomide without (arm A) or with (arm B) ESA\/G-CSF. In arm B, patients without erythroid response (HI-E) after 4 cycles received ESA; G-CSF was added if no HI-E was obtained by cycle 9. HI-E served as primary endpoint. Flow cytometry and next-generation sequencing were performed to identify predictors of response. The final evaluation comprised 184 patients; 84% non-del(5q), 16% isolated del(5q); median follow-up: 70.7 months. In arm A and B, 39 and 41% of patients achieved HI-E; median time-to-HI-E: 3.2 months for both arms, median duration of-HI-E: 9.8 months. HI-E was significantly lower in non-del(5q) vs. del(5q): 32% vs. 80%. The same accounted for transfusion independency-at-week 24 (16% vs. 67%), but similar in both arms. Apart from presence of del(5q), high percentages of bone marrow lymphocytes and progenitor B-cells, a low number of mutations, absence of ring sideroblasts, and SF3B1 mutations predicted HI-E. In conclusion, lenalidomide induced HI-E in patients with non-del(5q) and del(5q) MDS without additional effect of ESA\/G-CSF. The identified predictors of response may guide application of lenalidomide in lower-risk MDS in the era of precision medicine. (EudraCT 2008-002195-10).<\/jats:p>","DOI":"10.1038\/s41375-024-02161-6","type":"journal-article","created":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T13:03:18Z","timestamp":1706706198000},"page":"840-850","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial"],"prefix":"10.1038","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8311-983X","authenticated-orcid":false,"given":"A. A.","family":"van de Loosdrecht","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. M. P.","family":"Cremers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Alhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Duetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. E. M.","family":"in \u2019t Hout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. A.","family":"Visser-Wisselaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. A.","family":"Chitu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Verbrugge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. M.","family":"Cunha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. J.","family":"Ossenkoppele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. J. W. M.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8847-2704","authenticated-orcid":false,"given":"S. K.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Vellenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. A.","family":"Huls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Muus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. M. C.","family":"Langemeijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. E.","family":"de Greef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. A. W.","family":"te Boekhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. H. G.","family":"Raaijmakers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"van Marwijk Kooy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. C.","family":"Legdeur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. J.","family":"Wegman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Deenik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"de Weerdt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. M.","family":"van Maanen-Lamme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Jobse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. J. W.","family":"van Kampen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Beeker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. W.","family":"Wijermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. J.","family":"Biemond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. C.","family":"Tanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. W. J.","family":"van Esser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2730-9353","authenticated-orcid":false,"given":"C. G.","family":"Schaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. S.","family":"Noordzij-Nooteboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. M. G.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. O.","family":"de Graaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Jongen-Lavrencic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. J. P. L.","family":"Stevens-Kroef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. M.","family":"Westers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. H.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,31]]},"reference":[{"key":"2161_CR1","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1182\/blood-2013-03-492884","volume":"122","author":"L Malcovati","year":"2013","unstructured":"Malcovati L, Hellstrom-Lindberg E, Bowen D, Ades L, Cermak J, Del Canizo C, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013;122:2943\u201364.","journal-title":"Blood"},{"key":"2161_CR2","doi-asserted-by":"publisher","first-page":"3607","DOI":"10.1200\/JCO.2007.15.4906","volume":"26","author":"M Jadersten","year":"2008","unstructured":"Jadersten M, Malcovati L, Dybedal I, Della Porta MG, Invernizzi R, Montgomery SM, et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol. 2008;26:3607\u201313.","journal-title":"J Clin Oncol"},{"key":"2161_CR3","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.beha.2013.09.007","volume":"26","author":"E Hellstr\u00f6m-Lindberg","year":"2013","unstructured":"Hellstr\u00f6m-Lindberg E, van de Loosdrecht A. Erythropoiesis stimulating agents and other growth factors in low-risk MDS. Best Pract Res Clin Haematol. 2013;26:401\u201310.","journal-title":"Best Pract Res Clin Haematol"},{"key":"2161_CR4","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/bjh.15707","volume":"184","author":"S Park","year":"2019","unstructured":"Park S, Greenberg P, Yucel A, Farmer C, O\u2019Neill F, De Oliveira Brandao C, et al. Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: a systematic literature review. Br J Haematol. 2019;184:134\u201360.","journal-title":"Br J Haematol"},{"key":"2161_CR5","doi-asserted-by":"publisher","first-page":"3765","DOI":"10.1182\/blood-2011-01-330126","volume":"118","author":"P Fenaux","year":"2011","unstructured":"Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mufti G, Mittelman M, et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-\/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood. 2011;118:3765\u201376.","journal-title":"Blood"},{"key":"2161_CR6","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1200\/JCO.2015.66.0118","volume":"34","author":"V Santini","year":"2016","unstructured":"Santini V, Almeida A, Giagounidis A, Gr\u00f6pper S, Jonasova A, Vey N, et al. Randomized phase III study of lenalidomide versus placebo in RBC transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes and ineligible for or refractory to erythropoiesis-stimulating agents. J Clin Oncol. 2016;34:2988\u201396.","journal-title":"J Clin Oncol"},{"key":"2161_CR7","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/leu.2015.296","volume":"30","author":"A Toma","year":"2016","unstructured":"Toma A, Kosmider O, Chevret S, Delaunay J, Stamatoullas A, Rose C, et al. Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion. Leukemia. 2016;30:897\u2013905.","journal-title":"Leukemia"},{"key":"2161_CR8","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1200\/JCO.20.01691","volume":"39","author":"AF List","year":"2021","unstructured":"List AF, Sun Z, Verma A, Bennett JM, Komrokji RS, McGraw K, et al. Lenalidomide-epoetin alfa versus lenalidomide monotherapy in myelodysplastic syndromes refractory to recombinant erythropoietin. J Clin Oncol. 2021;39:1001\u20139.","journal-title":"J Clin Oncol"},{"key":"2161_CR9","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1126\/science.1244851","volume":"343","author":"J Kr\u00f6nke","year":"2014","unstructured":"Kr\u00f6nke J, Udeshi ND, Narla A, Grauman P, Hurst SN, McConkey M, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014;343:301\u20135.","journal-title":"Science"},{"key":"2161_CR10","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/nature14610","volume":"523","author":"J Kr\u00f6nke","year":"2015","unstructured":"Kr\u00f6nke J, Fink EC, Hollenbach PW, MacBeth KJ, Hurst SN, Udeshi ND, et al. Lenalidomide induces ubiquitination and degradation of CK1\u03b1 in del(5q) MDS. Nature. 2015;523:183\u20138.","journal-title":"Nature"},{"key":"2161_CR11","doi-asserted-by":"publisher","first-page":"e114249","DOI":"10.1371\/journal.pone.0114249","volume":"9","author":"KL McGraw","year":"2014","unstructured":"McGraw KL, Basiorka AA, Johnson JO, Clark J, Caceres G, Padron E, et al. Lenalidomide induces lipid raft assembly to enhance erythropoietin receptor signaling in myelodysplastic syndrome progenitors. PLoS ONE. 2014;9:e114249.","journal-title":"PLoS ONE"},{"key":"2161_CR12","doi-asserted-by":"publisher","first-page":"3531","DOI":"10.1158\/0008-5472.CAN-15-1756","volume":"76","author":"AA Basiorka","year":"2016","unstructured":"Basiorka AA, McGraw KL, De Ceuninck L, Griner LN, Zhang L, Clark JA, et al. Lenalidomide stabilizes the erythropoietin receptor by inhibiting the E3 ubiquitin ligase RNF41. Cancer Res. 2016;76:3531\u201340.","journal-title":"Cancer Res"},{"key":"2161_CR13","doi-asserted-by":"publisher","first-page":"e26494","DOI":"10.4161\/onci.26494","volume":"2","author":"M Semeraro","year":"2013","unstructured":"Semeraro M, Vacchelli E, Eggermont A, Galon J, Zitvogel L, Kroemer G, et al. Trial watch: lenalidomide-based immunochemotherapy. Oncoimmunology. 2013;2:e26494.","journal-title":"Oncoimmunology"},{"key":"2161_CR14","doi-asserted-by":"publisher","first-page":"e133","DOI":"10.1111\/bjh.16558","volume":"189","author":"V Adema","year":"2020","unstructured":"Adema V, Palomo L, Toma A, Kosmider O, Fuster-Tormo F, Benito R, et al. Distinct mutational pattern of myelodysplastic syndromes with and without 5q- treated with lenalidomide. Br J Haematol. 2020;189:e133\u20137.","journal-title":"Br J Haematol"},{"key":"2161_CR15","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/s41375-020-0961-3","volume":"35","author":"V Santini","year":"2021","unstructured":"Santini V, Fenaux P, Giagounidis A, Platzbecker U, List AF, Haferlach T, et al. Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients. Leukemia. 2021;35:897\u2013900.","journal-title":"Leukemia"},{"key":"2161_CR16","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","volume":"100","author":"JW Vardiman","year":"2002","unstructured":"Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292\u2013302.","journal-title":"Blood"},{"key":"2161_CR17","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","volume":"108","author":"BD Cheson","year":"2006","unstructured":"Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419\u201325.","journal-title":"Blood"},{"key":"2161_CR18","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1038\/leu.2012.30","volume":"26","author":"TM Westers","year":"2012","unstructured":"Westers TM, Ireland R, Kern W, Alhan C, Balleisen JS, Bettelheim P, et al. Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group. Leukemia. 2012;26:1730\u201341.","journal-title":"Leukemia"},{"key":"2161_CR19","doi-asserted-by":"publisher","first-page":"e0171983","DOI":"10.1371\/journal.pone.0171983","volume":"12","author":"S Sandmann","year":"2017","unstructured":"Sandmann S, de Graaf AO, van der Reijden BA, Jansen JH, Dugas M. GLM-based optimization of NGS data analysis: a case study of Roche 454, Ion Torrent PGM and Illumina NextSeq sequencing data. PLoS ONE. 2017;12:e0171983.","journal-title":"PLoS ONE"},{"key":"2161_CR20","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405.","journal-title":"Blood"},{"key":"2161_CR21","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1182\/blood-2002-09-2768","volume":"102","author":"DA Wells","year":"2003","unstructured":"Wells DA, Benesch M, Loken MR, Vallejo C, Myerson D, Leisenring WM, et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood. 2003;102:394\u2013403.","journal-title":"Blood"},{"key":"2161_CR22","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.3324\/haematol.2011.048421","volume":"97","author":"MG Della Porta","year":"2012","unstructured":"Della Porta MG, Picone C, Pascutto C, Malcovati L, Tamura H, Handa H, et al. Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study. Haematologica. 2012;97:1209\u201317.","journal-title":"Haematologica"},{"key":"2161_CR23","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3324\/haematol.2016.147843","volume":"102","author":"EMP Cremers","year":"2017","unstructured":"Cremers EMP, Westers TM, Alhan C, Cali C, Visser-Wisselaar HA, Chitu DA, et al. Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes. Haematologica. 2017;102:320\u20136.","journal-title":"Haematologica"},{"key":"2161_CR24","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1056\/NEJMoa061292","volume":"355","author":"A List","year":"2006","unstructured":"List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355:1456\u201365.","journal-title":"N Engl J Med"},{"key":"2161_CR25","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/ejh.12380","volume":"93","author":"A Giagounidis","year":"2014","unstructured":"Giagounidis A, Mufti GJ, Mittelman M, Sanz G, Platzbecker U, Muus P, et al. Outcomes in RBC transfusion-dependent patients with Low-\/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study. Eur J Haematol. 2014;93:429\u201338.","journal-title":"Eur J Haematol"},{"key":"2161_CR26","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1038\/leu.2015.340","volume":"30","author":"E Schuler","year":"2016","unstructured":"Schuler E, Giagounidis A, Haase D, Shirneshan K, B\u00fcsche G, Platzbecker U, et al. Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5). Leukemia. 2016;30:1580\u20132.","journal-title":"Leukemia"},{"key":"2161_CR27","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1182\/blood-2018-06-857102","volume":"133","author":"U Platzbecker","year":"2019","unstructured":"Platzbecker U, Fenaux P, Ad\u00e8s L, Giagounidis A, Santini V, van de Loosdrecht AA, et al. Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials. Blood. 2019;133:1020\u201330.","journal-title":"Blood"},{"key":"2161_CR28","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1182\/blood-2013-07-512442","volume":"122","author":"V Santini","year":"2013","unstructured":"Santini V, Schemenau J, Levis A, Balleari E, Sapena R, Ad\u00e8s L, et al. Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS? Blood. 2013;122:2286\u20138.","journal-title":"Blood"},{"key":"2161_CR29","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/leu.2017.305","volume":"32","author":"G Kerdivel","year":"2018","unstructured":"Kerdivel G, Chesnais V, Becht E, Toma A, Cagnard N, Dumont F, et al. Lenalidomide-mediated erythroid improvement in non-del(5q) myelodysplastic syndromes is associated with bone marrow immuno-remodeling. Leukemia. 2018;32:558\u201362.","journal-title":"Leukemia"},{"key":"2161_CR30","doi-asserted-by":"publisher","first-page":"e220","DOI":"10.3324\/haematol.2014.116657","volume":"100","author":"JD Kahn","year":"2015","unstructured":"Kahn JD, Chamuleau ME, Westers TM, Van de Ven PM, van Dreunen L, van Spronsen M, et al. Regulatory T cells and progenitor B cells are independent prognostic predictors in lower risk myelodysplastic syndromes. Haematologica. 2015;100:e220\u20132.","journal-title":"Haematologica"},{"key":"2161_CR31","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/cyto.b.22044","volume":"104","author":"AA van de Loosdrecht","year":"2023","unstructured":"van de Loosdrecht AA, Kern W, Porwit A, Valent P, Kordasti S, Cremers EMP, et al. Clinical application of flow cytometry in patients with idiopathic cytopenias and suspected myelodysplastic syndrome: a report of the International Consortium and the European LeukemiaNet Working Group. Cytometry B Clin Cytom. 2023;104:77\u201386.","journal-title":"Cytometry B Clin Cytom"},{"key":"2161_CR32","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1182\/blood.2020004850","volume":"136","author":"L Malcovati","year":"2020","unstructured":"Malcovati L, Stevenson K, Papaemmanuil E, Neuberg D, Bejar R, Boultwood J, et al. SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. Blood. 2020;136:157\u201370.","journal-title":"Blood"},{"key":"2161_CR33","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.3324\/haematol.2017.166173","volume":"102","author":"M Meggendorfer","year":"2017","unstructured":"Meggendorfer M, Haferlach C, Kern W, Haferlach T. Molecular analysis of myelodysplastic syndrome with isolated deletion of the long arm of chromosome 5 reveals a specific spectrum of molecular mutations with prognostic impact: a study on 123 patients and 27 genes. Haematologica. 2017;102:1502\u201310.","journal-title":"Haematologica"},{"key":"2161_CR34","doi-asserted-by":"publisher","first-page":"eaan4673","DOI":"10.1126\/science.aan4673","volume":"366","author":"S Jaiswal","year":"2019","unstructured":"Jaiswal S, Ebert BL. Clonal hematopoiesis in human aging and disease. Science. 2019;366:eaan4673.","journal-title":"Science"},{"key":"2161_CR35","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1056\/NEJMoa1908892","volume":"382","author":"P Fenaux","year":"2020","unstructured":"Fenaux P, Platzbecker U, Mufti GJ, Garcia-Manero G, Buckstein R, Santini V, et al. Luspatercept in patients with lower-risk myelodysplastic syndromes. N Engl J Med. 2020;382:140\u201351.","journal-title":"N Engl J Med"},{"key":"2161_CR36","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia"},{"key":"2161_CR37","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1080\/10428194.2021.1971217","volume":"63","author":"R Komrokji","year":"2022","unstructured":"Komrokji R, Melody M, Al Ali N, Chan O, Klimek V, Ball BJ, et al. Treatment outcomes for patients with myelodysplastic syndrome\/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis. Leuk Lymphoma. 2022;63:199\u2013204.","journal-title":"Leuk Lymphoma"},{"key":"2161_CR38","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.3324\/haematol.2014.115725","volume":"100","author":"U Oelschlaegel","year":"2015","unstructured":"Oelschlaegel U, Westers TM, Mohr B, Kramer M, Parmentier S, Sockel K, et al. Myelodysplastic syndromes with a deletion 5q display a characteristic immunophenotypic profile suitable for diagnostics and response monitoring. Haematologica. 2015;100:e93\u20136.","journal-title":"Haematologica"},{"key":"2161_CR39","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1111\/bjh.17414","volume":"193","author":"C Duetz","year":"2021","unstructured":"Duetz C, Westers TM, In \u2018t Hout FEM, Cremers EMP, Alhan C, Venniker-Punt B, et al. Distinct bone marrow immunophenotypic features define the splicing factor 3B subunit 1 (SF3B1)-mutant myelodysplastic syndromes subtype. Br J Haematol. 2021;193:798\u2013803.","journal-title":"Br J Haematol"},{"key":"2161_CR40","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/cyto.b.22057","volume":"104","author":"E Wei\u00df","year":"2023","unstructured":"Wei\u00df E, Walter W, Meggendorfer M, Baer C, Haferlach C, Haferlach T, et al. Identification of a specific immunophenotype associated with a consistent pattern of genetic mutations including SRFS2 and gene expression profile in MDS. Cytometry B Clin Cytom. 2023;104:173\u201382.","journal-title":"Cytometry B Clin Cytom"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02161-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02161-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02161-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T15:02:28Z","timestamp":1712329348000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02161-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,31]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["2161"],"URL":"https:\/\/doi.org\/10.1038\/s41375-024-02161-6","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,31]]},"assertion":[{"value":"30 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AL: research support: Celgene\/BMS, Roche, Alexion; advisory boards: Celgene\/BMS, Amgen, Novartis, Pfizer, AbbVie, Syros; speakers fee: Celgene\/BMS, Novartis, Takeda. PM: advisory boards: Novartis; speakers fee: Sobi. PB: advisory boards: AbbVie; speakers fee: Novartis. JJ: research support: Novartis, BMS. President, Apps for Care and Science, nonprofit. foundation supported by Amgen, Astellas, Daiichi-Sankyo, Janssen, Olympus, Incyte, BMS, Sanofi Genzyme, Servier, Jazz, Takeda. Honoraria: Abbvie, Novartis, Pfizer, Incyte. All other authors declared no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}